DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
SEARCH
Endroit courant :
>
> This Story


Ouverture ou Registre to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Business Affairs Homepage

Installing and removing imaging equipment is no small task Expert insights on how project management is evolving

Canon, Toshiba each hit with $2.5 million fine over acquisition deal Deal violated premerger notification and waiting period requirements

GE likely to hold onto NY digital X-ray detector manufacturing plant — for now New York State facility employs 125 workers

Ohio radiology services president indicted in Medicare scam Charged for services never provided and received nearly $2 million

Getting ahead of the digital health avalanche How can a health system know which innovative tools are worth its time?

Half of radiologists have net worth of $2 million or more New survey analyzed responses from over 20,000 physicians in over 30 specialties

Varian to acquire Cancer Treatment Services International for $283 million Enables production of multidisciplinary solutions

FBI opens probe into alleged kickbacks by healthcare OEMs in Brazil Accused of making bribes to sell medical equipment

icometrix raises $18 million in funding Will help with deployment of icobrain software in Europe

Q&A with Michael Darling, VP Supply Chain, St. Luke’s Health System Discussing the clinical integration of supply chain

Johnson & Johnson to acquire Auris Health for $3.4 billion

par Thomas Dworetzky , Contributing Reporter
Johnson & Johnson has said that Ethicon, part of the Johnson & Johnson Medical Devices Companies, has agreed to buy Auris Health Inc., for approximately $3.4 billion in cash – with as much as an additional $2.35 billion added to the price-tag – if certain milestones are hit.

The deal furthers J&J's move into robotics, according to the company statement. It is expected to close by the end of the second quarter of 2019.

Story Continues Below Advertisement

THE (LEADER) IN MEDICAL IMAGING TECHNOLOGY SINCE 1982. SALES-SERVICE-REPAIR

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.



Privately held Auris develops robotic techniques – currently centering around the treatment of lung cancer. Its Monarch platform is FDA-cleared for diagnostic and therapeutic bronchoscopic procedures.

“In this new era of health care, we’re aiming to simplify surgery, drive efficiency, reduce complications and improve outcomes for patients, ultimately making surgery safer,” Ashley McEvoy, executive vice president, worldwide chairman, Medical Devices, Johnson & Johnson, said in the statement announcing the deal, adding that, “we believe the combination of best-in-class robotics, advanced instrumentation and unparalleled end-to-end connectivity will make a meaningful difference in patient outcomes.”

Auris founder and CEO Dr. Frederic Moll, is joining Johnson & Johnson as part of the deal.

“We’re thrilled to be joining Johnson & Johnson to help push the boundaries of what is possible in medical robotics and improve the lives of patients across the globe,” he said in a statement.

The hope is that the deal will “dramatically accelerate our collective product innovation to develop new interventional solutions that redefine optimal patient outcomes,” he added.

The move, according to the companies, will permit further disruption of the medical innovation market. “With Auris Health’s current focus on lung cancer, the Monarch Platform robotic technology will play an important role within the Lung Cancer Initiative at Johnson & Johnson, enabling the development of a differentiated digital solution that addresses key steps in the lung cancer care journey, from diagnosis to early stage intervention, that are central to the company’s commitment to develop solutions that prevent, intercept and cure this deadly disease.”

The Auris Health technology will also find application in other Johnson & Johnson foci of interest, including open, laparoscopic, robotic and endoluminal surgical approaches.

It fits in with the company's recent acquisitions in the robotic space.

In February, 2018, the company acquired Orthotaxy, a software-enabled surgery technology developer. The move gave Johnson & Johnson access to its proprietary technology in early stage development for total and partial knee replacement.
  Pages: 1 - 2 >>

Business Affairs Homepage


You Must Be Logged In To Post A Comment

La publicité d'email
Développez la notoriété de votre marque
Enchères + Ventes Privées
Obtenir le meilleur prix
Acheter des équipement / pièces
Trouver le meilleur prix
Infos du jour
Lire Les dernières nouvelles
Annuaire
Consulter tous les utilisateurs DOTmed
Éthique concernant DOTmed
Voir notre programme d'éthique
L'or partie le programme de fournisseur
Recevoir des demandes PH
Programme de marchand de service d'or
Recevoir des demandes
Fournisseurs de soins de santé
Voir tous les outils des HCP (abréviation pour les professionnels de la santé)
Jobs/Formation
Trouver / combler un poste
Parts Hunter +EasyPay
Obtenir des devis de pièces
Voir les utilisateurs récemment certifiés
Voir les utilisateurs récemment certifiés
Récemment évalué sur DOTmed
Voir les utilisateurs récemment certifiés
Central de location
Louer de l’équipement à moindre prix
Vendre des équipements / pièces
Obtenir le maximum d'argent
Service Technicians Forum
Trouver de l'aide et des conseils
Simple demande de propositions
Obtenir des devis pour des appareils
Expo Virtuelle
Trouver des services d'appareils
L'Access et l'utilisation de cet emplacement est sujet aux modalités et aux conditions du notre de nos MENTIONS LEGALES & DONNEES PERSONELLES
Propriété de et classe des propriétaires DOTmedà .com, inc. Copyright ©2001-2019 DOTmed.com, Inc.
TOUS DROITS RÉSERVÉS